• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

Sanofi taps Denali to help tackle neurodegenerative, inflammatory diseases in $1B-plus collaboration

Nov. 2, 2018
By Michael Fitzhugh
Sanofi SA's Genzyme Corp. has agreed to pay Denali Therapeutics Inc. $125 million to kickstart development of multiple small-molecule inhibitors of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a signaling protein that regulates inflammation and cell death in a variety of diseases. The candidates could potentially benefit people with Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Should all succeed, Denali could earn nearly $1.1 billion in milestone payments from Sanofi.
Read More

Strongbridge brightens shares, balance sheet with Macrilen sale to Novo Nordisk

Nov. 1, 2018
By Michael Fitzhugh
Shares of Strongbridge Biopharma plc (NASDAQ:SBBP) climbed 58 percent Wednesday to close at $6.40 as Novo Nordisk A/S agreed to pay $145 million plus royalties for U.S. and Canadian rights to the adult growth hormone deficiency therapy (AGHD) Macrilen (macimorelin), rights that Strongbridge itself had purchased less than a year ago from Aeterna Zentaris Inc. for $24 million up front. Novo also made an equity investment in the company.
Read More

Dicerna inks expansive, potentially lucrative RNAi deal with Lilly

Oct. 30, 2018
By Michael Fitzhugh
Eli Lilly and Co. has agreed to pay Dicerna Pharmaceuticals Inc. $100 million up front while investing $100 million more in the company as part of a new licensing and research collaboration agreement focused on the discovery, development and commercialization of medicines aimed at "more than 10 targets" in cardiometabolic disease, neurodegeneration and pain indications.
Read More

Syndax shares sink on phase III PFS miss for entinostat

Oct. 29, 2018
By Michael Fitzhugh
Shares of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) fell 17.1 percent to $5.01 Friday on news that adding its HDAC inhibitor, entinostat, to an aromatase inhibitor failed to deliver a statistically significant improvement in the length of time women with hormone receptor-positive, HER2-negative breast cancer lived without worsening of their cancers. The outcome, from the ongoing phase III study E2112, dashed hopes of an early regulatory filing, putting the focus on the trial's other co-primary endpoint, overall survival (OS).
Read More

89bio advancing Teva-sourced NASH asset with $60M series A

Oct. 26, 2018
By Michael Fitzhugh
89bio Ltd., a San Francisco-based startup focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, has closed a $60 million series A financing to advance an asset acquired from Israel's Teva Pharmaceutical Industries Ltd. through proof of concept. Currently in phase I testing, the long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue arrived at the company with positive preclinical data and an approved investigational new drug application.
Read More

Alexion taps Dicerna in $637M RNAi deal targeting complement-mediated diseases

Oct. 25, 2018
By Michael Fitzhugh
Alexion Pharmaceuticals Inc. has negotiated an exclusive license to develop and commercialize up to four preclinical RNAi molecules for complement-mediated diseases using Dicerna Pharmaceuticals Inc.'s liver-focused gene-silencing platform, GalXC. Dicerna will receive $22 million up front and an equity investment of $15 million for the first two candidates and stands to receive $20 million more if Alexion exercises an option to advance preclinical GalXC RNAi molecules for two additional targets within the complement pathway.
Read More

Zymeworks paves path to pipeline expansion with $480M-plus Leo Pharma deal

Oct. 24, 2018
By Michael Fitzhugh
Zymeworks Inc. has been recruited by Denmark's Leo Pharma A/S to help discover and develop new bispecific antibodies for dermatology indications. That the deal's value could exceed $480 million might be the headliner for companies that have yet to capture big pharma's attention. Zymeworks, by contrast, has already inked technology deals with Merck & Co. Inc., Glaxosmithkline plc, Janssen Biotech Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co. and Celgene Corp.
Read More

Adaptimmune counsels patience as shares tumble on early TCR data

Oct. 23, 2018
By Michael Fitzhugh
Initial data from ongoing studies of two T-cell receptor (TCR) programs presented by Adaptimmune Therapeutics plc at the European Society for Medical Oncology 2018 Congress showed what Rafael Amado, the company's president of R&D, called encouraging safety, "dose appropriate persistence and expansion, and early but transient evidence of antitumor activity in one ovarian cancer patient."
Read More

TP Therapeutics' bid to tackle cancer resistance backed with $80M round

Oct. 22, 2018
By Michael Fitzhugh
Privately held cancer drug developer TP Therapeutics Inc. said a newly completed $80 million mezzanine financing will help move its lead candidate, repotrectinib, into a potentially pivotal phase II study in early 2019. The company, which is at first targeting ROS1-positive non-small-cell lung cancer (NSCLC) and NTRK-positive solid tumors, specializes in addressing treatment resistance.
Read More

Startups deploying an expanded toolbox to tackle Alzheimer's disease

Oct. 19, 2018
By Michael Fitzhugh
SAN FRANCISCO – Dynamic as ever in the wake of this summer's mixed news on Biogen Inc. and Eisai Co. Ltd.'s anti-beta-amyloid approach, drug developers in the Alzheimer's field are increasingly looking to genetics and biomarkers as they seek new paths of attack for the global scourge. Now, with the success of precision approaches in cancer, scientists are also beginning to think about combination approaches to the complex neurodegenerative disease, representatives of Denali Therapeutics Inc., E-Scape Bio Inc., Alkahest Inc. and Neurotrope Inc. said Thursday at the BIO Investor Forum.
Read More
Previous 1 2 … 77 78 79 80 81 82 83 84 85 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe